研究单位：[1]Janssen Research & Development, LLC[2]Beijing Tiantan Hospital, Capital Medical University,Beijing, China, 100050[3]Xuanwu Hospital, Capital Medical University,Beijing, China, 100053[4]Beijing Hospital,Beijing, China, 100730[5]Peking Union Medical College Hospital,Beijing, China, 100730[6]The First Bethune Hospital of Jilin University,Changchun, China, 130021[7]Central South University Xiangya Hospital The First Affiliated Hospital of Hunan Medical College,Changsha, China, 410008[8]West China Hospital of Sichuan University,Chengdu, China, 610041[9]Fujian Medical University Union Hospital,Fuzhou, China, 350001[10]The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine,Guangzhou, China, 510405[11]Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,Hangzhou, China, 310020[12]Qianfoshan hospital of Shandong Province,Jinan, China, 250014[13]Qilu Hospital of Shandong University,Jinan, China, 250014[14]Huashan Hospital Fudan University,Shanghai, China, 200040[15]Tianjin Medical University General Hospital,Tianjin, China, 300052[16]The Second Affiliated Hospital of Air Force Medical University - Tangdu Hospital,Xi'An, China, 710038[17]Medicity S.A.S,Bucaramanga, Colombia, 681012[18]Fundacion Cardiovascular de Colombia,Floridablanca, Colombia, 680004[19]Neurologie a rehabilitace Skopalíkova,Brno, Czechia, 615 00[20]Fakultni nemocnice Brno,Fakultni nemocnice Brno[21]Fakultni nemocnice Ostrava,Ostrava, Czechia, 70852[22]Vseobecna Fakultní Nemocnice,Praha, Czechia, 12808
研究目的：
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
